Orphan Drug Designation (ODD)

Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US

OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country…